Laboratory protocol for the digital multiplexed gene expression analysis of nasopharyngeal swab samples using the NanoString nCounter system.


Journal

F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320

Informations de publication

Date de publication:
2022
Historique:
accepted: 22 09 2022
entrez: 7 11 2022
pubmed: 8 11 2022
medline: 9 11 2022
Statut: epublish

Résumé

This paper describes a laboratory protocol to perform the NanoString nCounter Gene Expression Assay from nasopharyngeal swab samples.  It is urgently necessary to identify factors related to severe symptoms of respiratory infectious diseases, such as COVID-19, in order to assess the possibility of establishing preventive or preliminary therapeutic measures and to plan the services to be provided on hospital admission. At present, the samples recommended for microbiological diagnosis are those taken from the upper and/or the lower respiratory tract.  The NanoString nCounter Gene Expression Assay is a method based on the direct digital detection of mRNA molecules by means of target-specific, colour-coded probe pairs, without the need for mRNA conversion to cDNA by reverse transcription or the amplification of the resulting cDNA by PCR. This platform includes advanced analysis tools that reduce the need for bioinformatics support and also offers reliable sensitivity, reproducibility, technical robustness and utility for clinical application, even in RNA samples of low RNA quality or concentration, such as paraffin-embedded samples. Although the protocols for the analysis of blood or formalin-fixed paraffin-embedded samples are provided by the manufacturer, no corresponding protocol for the analysis of nasopharyngeal swab samples has yet been established. Therefore, the approach we describe could be adopted to determine the expression of target genes in samples obtained from nasopharyngeal swabs using the nCOUNTER technology.

Identifiants

pubmed: 36329793
doi: 10.12688/f1000research.103533.2
pmc: PMC9617068.2
doi:

Substances chimiques

DNA, Complementary 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

133

Informations de copyright

Copyright: © 2022 García Aranda M et al.

Déclaration de conflit d'intérêts

No competing interests were disclosed.

Auteurs

Marilina García Aranda (M)

Research and Innovation Unit, Hospital Costa del Sol, Marbella, 26903, Spain.
Surgery, Biochemistry and Immunology Department, University of Malaga, Malaga, 29071, Spain.
Translational Research in Cancer and Other Prevalent Chronic Diseases Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand. C/ Marqués de Beccaria nº3, Malaga, 29010, Spain.

Inmaculada López-Rodríguez (I)

Microbiology Unit (Clinical Analysis Laboratory), Hospital Costa del Sol, Marbella, 26903, Spain.

Susana García-Gutiérrez (S)

Kronikgune, Research Unit, Hospital Galdakao-Usansolo, Galdakao, Spain.

Maria Padilla-Ruiz (M)

Research and Innovation Unit, Hospital Costa del Sol, Marbella, 26903, Spain.
Translational Research in Cancer and Other Prevalent Chronic Diseases Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand. C/ Marqués de Beccaria nº3, Malaga, 29010, Spain.

Vanessa de Luque (V)

UGC Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Malaga, Malaga, Spain.
Medical Oncology Service (Group of Translational Research in Cancer Immunotherapy), Regional and Virgen de la Victoria University Hospitals, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, C/ Marqués de Beccaría n°3, Malaga, 29010, Spain.

Maria Luisa Hortas (ML)

Clinical Laboratories Area, Hospital Costa del Sol, Marbella, 26903, Spain.

Tatiana Diaz (T)

Andalusian Public Health System Biobank, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain.

Martina Álvarez (M)

UGC Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), University of Malaga, Malaga, Spain.

Isabel Barragan-Mallofret (I)

Translational Research in Immunotherapy for Cancer Group, Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, 29010, Spain.
Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Maximino Redondo (M)

Research and Innovation Unit, Hospital Costa del Sol, Marbella, 26903, Spain.
Surgery, Biochemistry and Immunology Department, University of Malaga, Malaga, 29071, Spain.
Translational Research in Cancer and Other Prevalent Chronic Diseases Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand. C/ Marqués de Beccaria nº3, Malaga, 29010, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH